By Michele Maatouk
Date: Wednesday 05 Aug 2026
(Sharecast News) - Eli Lilly lifted its full-year guidance on Wednesday as weight-loss jabs Mounjaro and Zepbound drove an increase in second-quarter sales.
| Currency | US Dollars |
| Share Price | $ 1,246.93 |
| Change Today | $ -8.47 |
| % Change | -0.67 % |
| 52 Week High | $1,281.49 |
| 52 Week Low | $695.33 |
| Volume | 1,875 |
| Shares Issued | 944.80m |
| Market Cap | $1,178,100m |
| RiskGrade | 179 |
| Strong Buy | 11 |
| Buy | 10 |
| Neutral | 5 |
| Sell | 1 |
| Strong Sell | 0 |
| Total | 27 |

| Time | Volume / Share Price |
| 16:04 | 213,667 @ $1,246.93 |
| 15:59 | 40 @ $1,247.77 |
| 15:59 | 40 @ $1,247.77 |
| 15:59 | 100 @ $1,247.71 |
| 15:59 | 40 @ $1,247.71 |
You are here: research